Bioverge
Venture Capital
Active
50
3M
35
6.25
0.24
1
- Stages of investment
- Areas of investment
Summary
In 2016 was created Bioverge, which is appeared as Corporate Investor.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Bioverge, startups are often financed by Venture University, VU Venture Partners, Thomas Glocer. The meaningful sponsors for the fund in investment in the same round are Thiel Capital, Techammer, Phil Libin.
We can highlight the next thriving fund investment areas, such as Artificial Intelligence, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight OccamzRazor. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
The fund was created by Neil Littman, Rick Gibb.
The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 1 - 5 millions dollars.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 50
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 6.25
- Follow on index
- 0.24
- Investments by industry
- Biotechnology (29)
- Health Care (21)
- Therapeutics (11)
- Medical Device (9)
- Medical (9) Show 35 more
- Investments by region
-
- United States (43)
- Ireland (1)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 357K
- Group Appearance index
- 0.38
- Avg. company exit year
- 5
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Eigen Therapeutics | 28 Feb 2022 | Seed | |||
| My Diabetes Tutor | 27 Jul 2023 | Seed |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.